N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies

Ming Lung Ho, Wei Ke Kuo, Lichieh J. Chu, I. Hsin Yeh, Chung Wei Fan, Hsin I. Chang, Cho Li Yuan, Ting Yu Chou, Hoang Yang Chen, Shih Wei Yang, Liang Che Chang, Minzhen Luo, Timothy H. Wu, Yi Feng I. Chang, Chia Jung Yu, Chung Ching Hua, Wailap V. Ng*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background/Aim: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. Patients and Methods: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. Results: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. Conclusion: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation.

Original languageEnglish
Pages (from-to)6317-6324
Number of pages8
JournalAnticancer Research
Issue number11
StatePublished - 2019


  • Biomarkers
  • Glycodelin
  • PAEP


Dive into the research topics of 'N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies'. Together they form a unique fingerprint.

Cite this